Clinical trials: Hepatic Cancer
Hepatocellular Carcinoma (HCC)
Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma
This study aimed to investigate the clinical utility of Annexin A2 serum level as a novel diagnostic marker of hepatocellular carcinoma (HCC) and to correlate its level with alpha fetoprotein the current marker ofhepatocellular…
- Trial name
- NCT02541149
- Testing
- blood sample
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma
Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis
Hepatocellular carcinoma (HCC) has a global importance due to its high rate of progression and high mortality rates. Significant risk factors for the development of HCC are metabolic syndrome, obesity and type 2 diabetes…
- Trial name
- NCT04763707
- Where
- Egypt
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sohag University
Hepatitis B, Hepatitis C
Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants
The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States (US) is relatively low. However, immigrant populations in the US from Asia and sub-Saharan Africa have substantially higher prevalence…
- Conditions
- Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- NCT02366286
- Where
- United States
- Volunteers
- 892 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Liver Neoplasms
Complicated Outcome Prediction After Liver Resection
Although mortality after liver surgery reduced during the last three decades to less than 2%, post-operative course is still complicated in a range of 20-50% of cases.The identification of one or few factors which could detect…
- Trial name
- NCT03577067
- Testing
- Liver resection for primary and secondary disease
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- University of Milan
Hepatocellular Carcinoma
Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma
OBJECTIVES 1. To investigate whether adjuvant IFN-α therapy can delay or reduce the 2-5 years recurrence rate in curatively resected HCC . 2.
- Trial name
- NCT00149565
- Testing
- IFN-α2b
- Where
- Taiwan
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Gastric Cancer, Esophageal Cancer
PAN-study: Pan-Cancer Early Detection Study (PAN)
The PAN-cancer Early Detection study or PAN-study is a prospective cross-sectional observational case-control study evaluating whether Breath Biopsy can differentiate between patients with and without different cancer types by…
- Conditions
- Gastric Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- NCT03756597
- Testing
- ReCIVA, CASPER
- Where
- United Kingdom
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Owlstone Ltd
Hepatocellular Carcinoma
Tumor Growth Factors in Hepatocellular Carcinoma
Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells.
- Trial name
- NCT00764140
- Testing
- tumor growth factor concentration
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatocellular Carcinoma
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Circulating free cell DNA (cfDNA) is extracellular fragmentation of nucleic acids that occurs both in plasma and serum. This kind of DNA which derived from the apoptotic/necrotic cells or the lysis of circulating tumor cells…
- Trial name
- NCT02036216
- Where
- 2 sites in United States, China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Comparison of Microwave and Radiofrequency Ablation for Liver
According to randomized controlled trial requirement, the therapeutic effectiveness of cooled-probe microwave ablation and radiofrequency ablation on early-stage hepatocellular carcinoma is compared to find a better approach for…
- Trial name
- NCT02539212
- Testing
- microwave ablation, radiofrequency ablation
- Where
- China
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Primary Liver Cancer
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare…
- Trial name
- NCT05353894
- Testing
- GNS561 oral tablets and capsules
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Genoscience Pharma
Hepatocellular Carcinoma
The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead
This study involves the combined use of the FDA approved device, LC Bead and the FDA approved drug, Doxorubicin for the treatment of primary hepatocellular carcinoma (HCC).
- Trial name
- NCT01259024
- Testing
- transarterial chemoembolization using a drug-eluting bead
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.
- Trial name
- NCT06797427
- Testing
- DPH001, Nexavar (Sorafenib)
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Disruptive Pharma
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Biobank for Cholestatic Liver Diseases.
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis…
- Conditions
- Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
- Trial name
- NCT03445585
- Where
- United States
- Volunteers
- 9,150 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Zhejiang University
Split or Whole Liver Transplantation? A Multicenter Retrospective Cohort Study of Patients With Benign and Malignant Liver Disease
The primary objective of this study was to assess the safety and feasibility of split liver transplantation(SLT) for adult hepatocellular carcinoma (HCC) patients, while comparing the prognostic disparities between adult SLT and…
- Trial name
- NCT06359496
- Testing
- No intervention factor
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
HCC - Hepatocellular Carcinoma
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD).
- Trial name
- ABATE-MASLD (NCT07285850)
- Testing
- Sequential treatment of bevacizumab combined with atezolizumab (sequential group), Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Metabolic Signature of Healthy Lifestyle and HCC
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and its incidence is increasing including in regions where hepatitis infection rates are low.
- Trial name
- NCT03356535
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Liver Cancer, Hepatocellular Carcinoma
Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC
Due to providing valuable clinical information while being minimally invasive, blood-based testing will most likely be a prerequisite for future large-scale screening of high-risk populations.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04221347
- Testing
- blood sampling
- Where
- Czechia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Military University Hospital, Prague
Solid Tumors
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
- Trial name
- NCT02063230
- Testing
- Selumetinib 50mg, Selumetinib 25mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca